You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for candesartan cilexetil; hydrochlorothiazide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00383929 ↗ Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg Completed AstraZeneca Phase 3 2006-09-01 In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5 mg to that of candesartan 32 mg alone in patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and candesartan/HCT 32/12.5 mg with that of candesartan 32 mg, respectively.
NCT00434967 ↗ Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo Completed AstraZeneca Phase 3 2007-01-01 The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.
NCT00621153 ↗ Candesartan Effect in Second Stage Arterial Hypertension Completed AstraZeneca Phase 4 2008-02-01 To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
NCT01012479 ↗ Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension Completed Takeda Phase 4 2009-10-01 The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.
NCT02016183 ↗ Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months) Completed Takeda 2009-04-01 The purpose of this study is to evaluate the safety and efficacy of long-term use of candesartan cilexetil / hydrochlorothiazide combination tablets (ECARD) Combination Tablets LD&HD in hypertensive patients in the routine clinical setting
NCT02094924 ↗ A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 Completed GlaxoSmithKline Phase 1 2014-04-17 This study is required to confirm the suitability of a candidate FDC of 16mg candesartan cilexetil/12.5mg HCTZ (GSK587323) formulation for further development and provide data to allow the design of a future pivotal bioequivalence study. This study aims to determine the relative bioavailability of a FDC tablet formulation of 16mg candesartan cilexetil/12.5mg HCTZ relative to the reference product of same fixed dose combination (16mg candesartan cilexetil/12.5mg HCTZ) in healthy adult humans. This will be an open-label, randomised, single dose, two-way crossover study. Each subject will participate in two treatment periods and will be randomized to one of two sequences and administered one of the two treatments, A or B, as per the randomization schedule. The two treatment periods will be separated by a washout period of 7 to 14 days to ensure the candesartan and HCTZ have been effectively eliminated from the subject between dosing occasions. The study will enroll 16 healthy subjects to ensure that 14 subjects complete the study as planned.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for candesartan cilexetil; hydrochlorothiazide

Condition Name

Condition Name for candesartan cilexetil; hydrochlorothiazide
Intervention Trials
Hypertension 5
Stage II Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for candesartan cilexetil; hydrochlorothiazide
Intervention Trials
Hypertension 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for candesartan cilexetil; hydrochlorothiazide

Trials by Country

Trials by Country for candesartan cilexetil; hydrochlorothiazide
Location Trials
Ukraine 2
Germany 2
Poland 1
United Kingdom 1
Malta 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for candesartan cilexetil; hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for candesartan cilexetil; hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for candesartan cilexetil; hydrochlorothiazide
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for candesartan cilexetil; hydrochlorothiazide

Sponsor Name

Sponsor Name for candesartan cilexetil; hydrochlorothiazide
Sponsor Trials
AstraZeneca 3
Takeda 2
GlaxoSmithKline 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for candesartan cilexetil; hydrochlorothiazide
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.